Epetraborole

MENLO PARK, Calif.--( BUSINESS WIRE )--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the quarter ended September 30, 2024 and provided an update from its ongoing analysis of data from the Phase 2 portion of the EBO-301 trial. “Treatment options for patients with refractory MAC lung disease are extremely limited. Many of these patients are significantly more challenging to convert microbiologically due to the microbial complexity of their infections as well as their very complex lung anatomy, and often experience severe clinical symptoms at this advanced stage of disease. The fact that epetraborole appears to have demonstrated improvements based on two patient reported outcome measures is highly encouraging,” said Stephen J. Ruoss, M.D., Professor of Medicine, Pulmonary and Critical Care Medicine at Stanford University School of Medicine. “By potentially improving both their quality of life and clinical outcomes, epetraborole represents a potentially significant advancement in treatment possibilities.” "We are encouraged by this recent data analysis, which indicate that epetraborole may provide clinical improvement in patients with treatment-refractory MAC lung disease, as measured by two patient-reported outcome instruments, including the same instrument recently selected for the primary endpoint in the Arikayce TN-MAC pivotal trial," stated Eric Easom, Co-Founder, Chairman, President, and Chief Executive Officer of AN2 Therapeutics. "We look forward to engaging with the FDA in the near-term to discuss next steps for the epetraborole program, including the potential reinitiation of a pivotal Phase 3 trial for treatment-refractory MAC lung disease.” Easom continued, “With a strong cash runway and optimized operating plan, we continue to advance our diverse pipeline of boron-based compounds to address unmet patient needs. This includes the recent strategic expansion into oncology, underscoring our dedication to innovating and improving patient outcomes across multiple therapeutic areas." Third Quarter & Recent Updates: Ongoing Analysis from Epetraborole Phase 2/3 Clinical Study in TR-MAC Lung Disease The Company has provided an update from its ongoing analysis of the Phase 2 portion of the EBO-301 Phase 2/3 study. Two PROs evaluated in the trial indicated statistically significant clinical response, the QOL-B Respiratory Domain (Table 1) and MACrO 2 (post-hoc analysis, Table 2), using continuous response measures instead of the binary responder methodology previously reported. Patients treated with epetraborole indicated clinical response using the same PRO instrument (QOL-B respiratory domain) and analysis method (least squares mean change from Baseline to Month 6) that was recently reported as the primary endpoint in the Arikayce ENCORE trial, after alignment with FDA. These EBO-301 PRO findings appear to align with FDA’s current recommendation for PRO-based primary endpoints in NTM-MAC trials. Table 1: Quality of Life – Bronchiectasis (QOL-B respiratory domain) (least squares mean change from Baseline to Month 6) * EBO-301 prespecified secondary endpoint Epetraborole + OBR (n=34) Placebo + OBR (n=35) LS Mean Difference p-value Change from Baseline to Month 6 7.20 0.30 6.90 0.0365 * Measures of patient improvement for QOL-B are shown by positive changes in the score measured from baseline. Epetraborole treated patients showed nominally statistically significant improvements in the QOL-B respiratory domain measured from baseline to month 6. The p-value is termed “nominal” because this was not the prespecified primary endpoint in the Phase 2 part of the trial. Table 2: MACrO 2 PRO (least squares mean) * Post-hoc analysis Epetraborole + OBR (n=34) Placebo + OBR (n=35) LS Mean Difference p-value Change from Baseline to Month 6 -12.91 -7.10 -5.81 0.0433 * Measures of patient improvement for MACrO 2 are shown by negative changes in the score measured from baseline. The least squares mean calculation for MACrO 2 utilized the same approach as the prespecified QOL-B LSM in the EBO-301 statistical analysis plan. Epetraborole treated patients showed nominally statistically significant improvements in MACrO 2 measured from baseline to month 6 in post-hoc analysis. There was a high rate of MAC resistance to background antimycobacterial therapies at baseline, including approximately one-third of the patients with macrolide resistance and 60% with amikacin resistance, indicators of the complexity of the patient population. Notably, there was no evidence of induced epetraborole resistance in isolates from patients treated with epetraborole. Further analysis showed no change in the previously reported safety profile; epetraborole was generally well-tolerated, with 2 (5%) discontinuations due to TEAEs in the epetraborole arm. Epetraborole: Next Steps The Company believes these findings are particularly noteworthy given the severe refractory status of the patients studied, and that improvements in QOL-B and MACrO 2 appear to align with FDA’s current guidance for the primary efficacy endpoint in NTM-MAC studies. The Company will seek an End-of-Phase 2 meeting with FDA in the first half of 2025, with the goal of leveraging insights from the Phase 2 results to evaluate potential reinitiation of a pivotal Phase 3 TR-MAC study. In addition, the Company also plans to seek alignment with the FDA on a statistical analysis plan for the 97 patients who completed six months of treatment in the Phase 3 portion of EBO-301 at the time the Company halted the trial in August 2024. The Company anticipates releasing top-line Phase 3 data from these patients in mid-2025, subject to the timing of discussions with the FDA. Other AN2 Boron Chemistry Pipeline Programs Chagas Disease During the quarter, the Company advanced preclinical activities aimed to initiate clinical studies in chronic Chagas disease, a disease that affects an estimated 6-7 million people worldwide, including approximately 300,000 in the U.S., and causes severe cardiac disease and death. The Company plans to initiate Phase 1 clinical development with AN2-502998 in mid-2025. Melioidosis The Company completed enrollment in a 200-patient observational trial for epetraborole in acute melioidosis in October 2024 and these data will inform a Phase 2 proof of concept study that is planned to initiate enrollment in the second half of 2025. Melioidosis is a deadly bacterial infection and global bioterrorism threat with a 90-day mortality rate of approximately 50% using standard of care (SOC) drugs ceftazidime or meropenem. The aim of the program is to meaningfully lower the expected mortality rate by dosing epetraborole on top of SOC. Boron Chemistry Pipeline Additional development programs are underway and focused on targets in infectious diseases and oncology with high unmet needs. The Company anticipates delivering up to three development compounds in 2025. Global Health In October, the Company announced that it received a second-year continuation of a research grant from the Bill & Melinda Gates Foundation to discover novel boron containing small molecules for the treatment of tuberculosis and malaria. The Company will continue its efforts to tackle global health disease through non-dilutive funding. Selected Third Quarter Financial Results Research and Development (R&D) Expenses: R&D expenses for the third quarter of 2024 were $8.3 million compared to $14.4 million for the same period during 2023 due to decreased clinical trial costs, personnel-related expenses, preclinical and research study expenses, consulting and outside services, and other costs, partially offset by an increase in chemistry manufacturing and controls activity. General and Administrative (G&A) Expenses: G&A expenses for the third quarter of 2024 were $3.5 million compared to $3.8 million for the same period during 2023 due to a decrease in professional services. Restructuring Charges: Restructuring charges for the third quarter of 2024 were $2.2 million due to severance payments and other employee termination-related expenses, partially offset by a reduction in stock-based compensation expense as a result of applying modification accounting for consulting agreements entered into with certain terminated employees. Other Income, Net: Other income, net for the third quarter of 2024 was $1.3 million compared to $1.5 million for the same period during 2023 due to lower cash, cash equivalents and investment balances. Net loss: Net loss for the third quarter of 2024 was $12.7 million, compared to $16.7 million for the same period during 2023. Cash Position: The Company had cash, cash equivalents, and investments of $93.4 million at September 30, 2024. Company restructuring initiatives resulted in a 50% reduction in expenditures, extending AN2’s expected cash runway through 2027. About AN2 Therapeutics, Inc. AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM, and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. For more information, please visit our website at www.an2therapeutics.com . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: the potential of the Company’s boron chemistry platform and early-stage pipeline programs; design, initiation and timing of the Company’s clinical trials and results; anticipated inflection points and related timing; cash runway and cost savings related to restructuring; analysis and expectations regarding data analysis from the Phase 2/3 trial in treatment-refractory MAC lung disease, including the potential to re-initiate Phase 3 development; regulatory meetings and pathway and alignment with FDA guidance; future development of epetraborole for other forms of NTM; development of AN2-502998 for Chagas disease; development of epetraborole for melioidosis; development of compounds for infectious diseases and oncology targets; global health initiatives and non-dilutive funding; and other statements that are not historical fact. These statements are based on AN2’s current estimates, expectations, plans, objectives and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: future trials of epetraborole in NTM-MAC and the ability to show clinical efficacy consistent with PRO-based data observed in prospective and post-hoc analyses to date; potential disruptions related to AN2’s ability to implement its plans for its internal boron chemistry platform and early-stage pipeline programs; timely enrollment of patients in AN2’s existing and future clinical trials; AN2’s ability to procure sufficient supply of its product candidates for its existing and future clinical trials; the potential for results from clinical trials to differ from preclinical, early clinical, preliminary or expected results; significant adverse events, toxicities or other undesirable side effects associated with AN2’s product candidates; the significant uncertainty associated with AN2’s product candidates ever receiving any regulatory approvals; continued funding by the National Institute of Allergy and Infectious Disease (NIAID) of AN2’s development program for melioidosis; AN2’s ability to obtain, maintain or protect intellectual property rights related to its current and future product candidates; implementation of AN2’s strategic plans for its business and product candidates; the sufficiency of AN2’s capital resources and need for additional capital to achieve its goals; global macroeconomic conditions and global conflicts and other risks, including those described under the heading “Risk Factors” in AN2’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, and AN2’s other reports filed with the U.S. Securities and Exchange Commission (SEC). These filings, when made, are available on the investor relations section of AN2’s website at www.an2therapeutics.com and on the SEC’s website at www.sec.gov . Forward-looking statements contained in this press release are made as of this date, and AN2 undertakes no duty to update such information except as required under applicable law. AN2 THERAPEUTICS, INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except share and per share data) (unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Operating expenses: Research and development $ 8,287 $ 14,429 $ 35,091 $ 39,952 General and administrative 3,484 3,751 10,856 10,868 Restructuring charge 2,243 — 2,243 — Total operating expenses 14,014 18,180 48,190 50,820 Loss from operations (14,014 ) (18,180 ) (48,190 ) (50,820 ) Other income, net 1,267 1,473 4,391 2,986 Net loss attributable to common stockholders $ (12,747 ) $ (16,707 ) $ (43,799 ) $ (47,834 ) Net loss per share attributable to common stockholders, basic and diluted $ (0.43 ) $ (0.65 ) $ (1.47 ) $ (2.22 ) Weighted-average number of shares used in computing net loss per share, basic and diluted 29,841,169 25,645,421 29,809,839 21,532,537 Other comprehensive loss: Unrealized (loss) gain on investments 139 (3 ) (163 ) 252 Comprehensive loss $ (12,608 ) $ (16,710 ) $ (43,962 ) $ (47,582 ) AN2 THERAPEUTICS, INC. CONDENSED BALANCE SHEETS (in thousands) September 30, 2024 (unaudited) December 31, 2023 Assets Current assets: Cash and cash equivalents $ 33,504 $ 15,647 Short-term investments 59,922 91,648 Prepaid expenses and other current assets 4,263 3,212 Long-term investments — 27,194 Other assets, long-term — 1,043 Total assets $ 97,689 $ 138,744 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 1,711 $ 2,676 Other current liabilities 8,306 11,367 Total liabilities 10,017 14,043 Stockholders’ equity 87,672 124,701 Total liabilities and stockholders’ equity $ 97,689 $ 138,744

Matinas BioPharma first reported in August that it had signed a non-binding term sheet for global licensing rights to MAT2203 for all future treatment indications. Image credit: Yellow_man / Shutterstock. Matinas BioPharma has halted all product development activities and fired 80% of its staff, including three members of senior management, in an effort to save resources after the partnership negotiations for its lead antifungal therapy were terminated. The company noted that the workforce reductions would occur with immediate effect. According to a Matinas press release, the company’s board is evaluating all alternatives, including the asset sale of MAT2203 (oral formulation of amphotericin B) and the potential wind-down and dissolution of the company. The company’s stock took a nosedive following the news. It is currently trading at $0.67, down by 65.2% compared to the market close yesterday (30 October). Martinas BioPharma’s market cap currently stands at $3.5m, with the company reporting cash reserves of $14.3m as of 30 June, as per the company’s Q2 financials. In August, Martinas reported that it had signed a non-binding term sheet for global licensing rights to MAT2203 for all future treatment indications. The company did not disclose the partner’s name or the financial details of the deal, only that it was preparing to start a Phase III registrational trial for the therapy following the partnership announcement. The study was expected to evaluate the therapy as an oral step-down monotherapy for patients with invasive aspergillosis following treatment with AmBisome (liposomal amphotericin B). MAT2203 was designed using the company’s lipid nanocrystal (LNC) platform to overcome the safety and toxicity limitations of intravenous amphotericin B. Despite being indicated to treat invasive fungal infections, intravenous amphotericin B is known to be toxic to kidneys and liver, with approximately 80% of patients developing infusion-related adverse effects or nephrotoxicity. Although there is an increased need for antimicrobial therapies , the field has not seen much success in recent years. Spero Therapeutics’ prodrug antibiotic SPR720 failed to meet the primary endpoint in a Phase IIa trial in patients with non-tuberculous mycobacterial pulmonary disease. AN2 Therapeutics also had to suspend development for its lead antibiotic, epetraborole, after it failed to show efficacy in the Phase II/III trial (NCT05327803). Itreum Therapeutics was able to receive approval from the US Food and Drug Administration (FDA) for its antibiotic Orlynvah (sulopenem etzadroxil and probenecid) for treating uncomplicated urinary tract infections (uUTIs). The agency approved the therapy’s use for treating uUTIs caused by E. coli, Klebsiella pneumoniae or Proteus mirabilis in women who have limited or no alternative antibacterial treatment options.